Lytix Biopharma AS will release its third quarter 2022 results on Thursday, 17
November 2022 at 08.00 a.m. CEST. The results will be presented in a webcast
with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 14.30 a.m.
CEST. 

We encourage you to send us questions, in advance, that can be addressed during
the Q&A session. Please send your email to post@lytixbiopharma.com. 

The presentation and subsequent Q&A session will be held in English and may be
viewed live at https://channel.royalcast.com/landingpage/hegnarmedia/20221117_4/


A recording of the presentation will be made available on
https://www.lytixbiopharma.com/investors/overview.html after the presentation. 


For more information, please contact: 
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com 

Lytix in brief: 
Based in Oslo, Norway, Lytix is a clinical stage biotech company developing
novel cancer immunotherapies, an area within cancer therapy that is aimed at
activating the patient's immune system to fight cancer. The company's technology
is based on pioneering research in "host defense peptides" - nature's first line
of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315,
is a first-in-class oncolytic molecule representing a new and superior
therapeutic principle to boost anti-cancer immunity, with the potential to be
the ideal combination partner with other types of immunotherapies. LTX-315
targets cancer cells and disintegrates their cell membranes, causing immunogenic
cell death and release of a patient's tumor specific antigens and potent
immunostimulants. This mode of action allows cytotoxic T cells to recognize,
infiltrate and attack cancer cells.